Current European clinical guidelines [60] recommend multimodal treatment of localised high-risk prostate cancer and ADT, commonly used to treat locally advanced and metastatic cancer, has been shown to cause an influx of CD8+ T-cells in the primary tumour [61]. Here, CD8A is linked to prostate cancer.